In this episode, ECDC expert on respiratory viruses, Nick Bundle, gives the lowdown on the European Respiratory Virus Surveillance Summary (ERVISS), a new surveillance tool which presents weekly data on influenza, SARS-CoV-2 and RSV.

The discussions highlighted the crucial role of prevention, treatment and access to immunisation programmes to raise awareness and decrease the cases of RSV hospitalisations and deaths of young children and older adults.

Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children.

Conclusions by Peter Openshaw, Co-Chair of the the ESWI Respiratory Virus Summit 2024

By Ab Osterhaus, Host of the ESWI Respiratory Virus Summit 2024

Live attenuated vaccines; NIRSE-GAL: Evaluation of the effectiveness and impact of Nirsevimab in Galicia; and Therapeutics

ESWI Summit 2024: Early Career Scientists They each delivered a presentation introducing themselves and their ongoing work on RSV, bringing innovative ideas and making clear calls for action.

Keynote Lecture by Dexter Wiseman, Imperial College London

Keynote Lecture by Stefan Gravenstein, Brown University

Keynote Lecture by Simon Drysdale, St George's University Hospitals NHS Foundation Trust

The purpose of NIRSE-GAL is to evaluate the impact of the inclusion of nirsevimab in the Galician immunisation schedule on the prevention of Respiratory Syncytial Respiratory Syncytial Virus (RSV) infections in children.

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTI) in children.